Skip to content

Study · Non-randomized trial · n = 20 · 2010

4 results

Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis.

Prasse A, Zissel G, Lützen N, Schupp J, Schmiedlin R, Gonzalez-Rey E, Rensing-Ehl A, Bacher G, Cavalli V, Bevec D, Delgado M, Müller-Quernheim J

American journal of respiratory and critical care medicine4 May 2010Cited by 102 (Europe PMC)

PMID20442436 (opens in a new tab)DOI10.1164/rccm.200909-1451oc (opens in a new tab)PepBankPUB-20442436
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In patients with active sarcoidosis, 4 weeks of nebulized VIP was reported as safe and well tolerated.

    In plain wordsIn people with active sarcoidosis, inhaled VIP for 4 weeks was reported as safe and well tolerated, in a study without a control group.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeSafety and tolerability of inhaled VIP
    Study

    n = 20

    Outcome group
    Adverse events · Respiratory
    Studied dose
    Dose not stated · nebulized inhalation · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    VIP inhalation was safe, well-tolerated
    1 context sentence
    Summary · context
    In an open clinical phase II study, we treated 20 patients with histologically proved sarcoidosis and active disease with nebulized VIP for 4 weeks.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with active sarcoidosis, nebulized VIP reduced the production of tumor necrosis factor-alpha by cells from bronchoalveolar lavage fluid.

    In plain wordsIn people with active sarcoidosis, inhaled VIP reduced the amount of the inflammatory signal TNF-alpha made by lung wash cells.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseTNF-alpha production by bronchoalveolar lavage cells
    Study

    n = 20

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · nebulized inhalation · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    VIP inhalation was safe, well-tolerated, and significantly reduced the production of tumor necrosis factor-alpha by cells isolated from bronchoalveolar lavage fluids of these patients.
    1 context sentence
    Summary · context
    In an open clinical phase II study, we treated 20 patients with histologically proved sarcoidosis and active disease with nebulized VIP for 4 weeks.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with active sarcoidosis, nebulized VIP increased the numbers of CD4(+)CD127(-)CD25(+) T cells with regulatory activity in bronchoalveolar lavage.

    In plain wordsIn people with active sarcoidosis, inhaled VIP raised the number of regulatory T cells in lung wash samples.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseRegulatory T cell numbers in bronchoalveolar lavage
    Study

    n = 20

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · nebulized inhalation · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    VIP treatment significantly increased the numbers of bronchoalveolar lavage CD4(+)CD127(-)CD25(+) T cells, which showed regulatory activities on conventional effector T cells.
    1 context sentence
    Summary · context
    In an open clinical phase II study, we treated 20 patients with histologically proved sarcoidosis and active disease with nebulized VIP for 4 weeks.
  4. 04LabIn vitro (cells)Mechanism

    In in vitro experiments, VIP converted naive CD4(+)CD25(-) T cells into CD4(+)CD25(+)FoxP3(+) regulatory T cells.

    In plain wordsIn lab tests, VIP turned immune cells of one type into regulatory T cells.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseConversion of naive T cells to regulatory T cells
    Study

    n: not reported in source

    Naive CD4(+)CD25(-) T cells in vitro
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro experiments demonstrated the capacity of VIP to convert naive CD4(+)CD25(-) T cells into CD4(+)CD25(+)FoxP3(+) regulatory T cells, suggesting the generation of peripheral regulatory T cells by VIP treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:40 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.